MedPath

Shanghai Jiaotong Medical University Attached Ruijin Hospital

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

511

Active:28
Completed:62

Trial Phases

6 Phases

Early Phase 1:12
Phase 1:41
Phase 2:102
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (357 trials with phase data)• Click on a phase to view related trials

Not Applicable
148 (41.5%)
Phase 2
102 (28.6%)
Phase 1
41 (11.5%)
Phase 4
34 (9.5%)
Phase 3
20 (5.6%)
Early Phase 1
12 (3.4%)

A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease

Not Applicable
Not yet recruiting
Conditions
Parkinson Disease (PD)
Gene Therapy
Safety and Efficacy
Clozapine
Interventions
Genetic: gene therapy
First Posted Date
2025-07-25
Last Posted Date
2025-07-25
Lead Sponsor
Ruijin Hospital
Target Recruit Count
6
Registration Number
NCT07085195
Locations
🇨🇳

Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

Not Applicable
Recruiting
Conditions
Colo-rectal Cancer
Third-line and Beyond Therapy
TAS 102
Bevacizumab
Interventions
Drug: Trifluridine/tipiracil (TAS-102) plus bevacizumab
First Posted Date
2025-07-25
Last Posted Date
2025-07-25
Lead Sponsor
Ruijin Hospital
Target Recruit Count
50
Registration Number
NCT07085169
Locations
🇨🇳

SanMing First Hospital, Sanming, China

🇨🇳

Ruijin Hospital, Shanghai, China

A Prospective Observational Cohort Study on Longitudinal Monitoring of ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer

Recruiting
Conditions
Pathologically Confirmed Pancreatic Cancer,High-risk Resectable, Borderline Resectable, or Locally Advanced Disease
First Posted Date
2025-07-23
Last Posted Date
2025-07-23
Lead Sponsor
Ruijin Hospital
Target Recruit Count
119
Registration Number
NCT07080021
Locations
🇨🇳

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China

🇨🇳

Ruijin hospital, Shanghai, China

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

Not Applicable
Not yet recruiting
Conditions
Peripheral T-Cell Lymphoma, Not Classified
Interventions
Drug: golidocitinib with azacytidine and chidamide
First Posted Date
2025-07-23
Last Posted Date
2025-07-23
Lead Sponsor
Ruijin Hospital
Target Recruit Count
30
Registration Number
NCT07081607

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Not Applicable
Recruiting
Conditions
B-cell Non-Hodgkin Lymphoma
Interventions
First Posted Date
2025-07-18
Last Posted Date
2025-07-18
Lead Sponsor
Ruijin Hospital
Target Recruit Count
56
Registration Number
NCT07072169
Locations
🇨🇳

Ruijin Hospital, Shanghai, Shanghai, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 102
  • Next

News

Zambon Secures Chinese Approval for Intravenous Fluimucil Following Successful Phase 3 Trial

Zambon has received Chinese regulatory approval and launched the intravenous formulation of Fluimucil (N-acetylcysteine) for treating respiratory diseases with excessive mucus secretion.

CirCode Biomed's HM2002 Becomes World's First Circular RNA Drug to Receive FDA IND Clearance for Ischemic Heart Disease

CirCode Biomed announced FDA clearance for HM2002, marking the first circular RNA drug to receive IND approval for ischemic heart disease treatment.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.